New obesity drug HM17321 enters first human safety trials
NCT ID NCT07219589
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug, HM17321, to see if it is safe and how the body processes it. About 90 healthy and obese adults will receive either the drug or a placebo as a shot under the skin. The main goal is to check for side effects, not to treat obesity yet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HM17321
What this could lead to
If successful, this could lead to a new injectable medication for weight management in people with obesity.
What could go wrong
This is a very early Phase 1 study focused on safety, not weight loss. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medpace Clinical Pharmacology Unit
RECRUITINGCincinnati, Ohio, 45227, United States
Contact